Maliuchenko N V, Kulaeva O I, Kotova E, Chupyrkina A A, Nikitin D V, Kirpichnikov M P, Studitskiĭ V M
Mol Biol (Mosk). 2015 Jan-Feb;49(1):99-113.
Poly-ADP-ribosylation is a covalent post-translational modification of nuclear proteins that plays a key role in the immediate response of cells to genotoxic stress. Poly(ADP-ribose) polymerase (PARP) synthesizes long and branched polymers of ADP-ribose onto acceptor regulator proteins, and thereby change their activity. Metabolism of poly-ADP regulates DNA repair, cell cycle, replication, aging and death of cells, as well as remodeling of chromatin structure and gene transcription. PARP1 is one of the most common nuclear proteins; it is responsible for production of -90% of the polymers of ADP-ribose in the cell. PARP1 inhibitors are promising antitumor agents. At the same time, the current inhibitors target the catalytic domain of PARP1 that leads to.a number of side effects. Therefore, considering the potential benefits of PARP1 inhibitors for the treatment of multiple diseases, it is necessary to develop new strategies of PARP1 inhibition. PARP1 has a modular structure and has catalytic, transcription and DNA-binding activities. The review focuses primarily on the role of PARP1 in transcriptional regulation; the structure and functional organization of PARP1, as well as multiple ways of regulation of chromatin remodeling, DNA methylation and transcription are covered in detail. Studies of the molecular mechanisms of regulation of transcription factor PARP1 can serve as a basis for search and design of new inhibitors.
多聚 ADP 核糖基化是一种核蛋白的共价翻译后修饰,在细胞对基因毒性应激的即时反应中起关键作用。多聚(ADP - 核糖)聚合酶(PARP)将 ADP - 核糖的长链和分支聚合物合成到受体调节蛋白上,从而改变它们的活性。多聚 ADP 的代谢调节 DNA 修复、细胞周期、复制、细胞衰老和死亡,以及染色质结构重塑和基因转录。PARP1 是最常见的核蛋白之一;它负责细胞中约 90%的 ADP - 核糖聚合物的产生。PARP1 抑制剂是很有前景的抗肿瘤药物。同时,目前的抑制剂靶向 PARP1 的催化结构域,这会导致一些副作用。因此,考虑到 PARP1 抑制剂对多种疾病治疗的潜在益处,有必要开发新的 PARP1 抑制策略。PARP1 具有模块化结构,具有催化、转录和 DNA 结合活性。本综述主要关注 PARP1 在转录调控中的作用;详细介绍了 PARP1 的结构和功能组织,以及染色质重塑、DNA 甲基化和转录的多种调控方式。对转录因子 PARP1 调控分子机制的研究可为新型抑制剂的寻找和设计提供依据。